Previous Close | 2.3800 |
Open | 2.4000 |
Bid | 2.4000 x 1400 |
Ask | 2.4800 x 800 |
Day's Range | 2.3500 - 2.5300 |
52 Week Range | 1.2600 - 6.8600 |
Volume | |
Avg. Volume | 352,750 |
Market Cap | 376.452M |
Beta (5Y Monthly) | 1.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0020 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.67 |
Today is shaping up negative for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...
- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress - - Quarterly call to be held today, August 4, 2022, at 8:00 a.m. EDT (1:00 p.m. BST) -Philadelphia, Pennsylvania, and Oxford, United Kingdom--(Newsfile Corp. - August 4, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), ...
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders should be happy to see the share price up 12% in the last...